The National Biodiversity Authority has collected Rs. 278 crore through its Access and Benefit Sharing framework since 2008. With over Rs. 9.68 crore contributed in the first half of the current fiscal year alone, this levy remains a persistent compliance cost for seed and agricultural companies. Investors should track how evolving traceability regulations and these recurring payments may impact long-term profit margins in the agro-input sector.
The National Biodiversity Authority (NBA) has collected Rs. 278 crore under the Access and Benefit Sharing (ABS) framework since its inception in 2008. This system, established under the Biological Diversity Act, requires commercial entities to pay for the utilization of biological resources, including agricultural crops, microbial strains, and animal genetic material. For the period between April and September 2026, the authority processed Rs. 9.68 crore in contributions, highlighting the ongoing financial impact of this regulation on the agro-industry.
Impact on the Seed and Agro-Input Sector
The seed and agricultural input sector has emerged as the primary contributor to this fund, accounting for 74% of the intake during the first half of the current fiscal year. Major companies, including East West Seeds India, Nunhems India, Bayer Science & Innovation, Syngenta India, and Enza Zaden India, are among the prominent entities participating in the framework.
Under the current rules, which were updated following the 2023 amendment to the Biological Diversity Act, companies with an annual turnover exceeding Rs. 5 crore are subject to levies. These payments, which can range from 0.2% to 0.6% of the ex-factory selling price of products derived from regulated biological resources, act as a mandatory compliance cost. For investors, this represents a recurring operational expense that can influence profit margins, particularly for firms with high volumes of products derived from specific biological assets.
The Traceability Challenge and Fund Distribution
A critical issue for both the regulator and the industry is the traceability of biological assets. When companies source materials through open markets or intermediaries, the direct link to the original farming communities is often lost. In such cases, the NBA redistributes the collected funds to state-level biodiversity boards based on cultivation acreage, rather than compensating individual farmers.
While this administrative approach is practical, critics have questioned whether it effectively reaches the grassroots recipients who historically preserved these genetic traits. For investors, the lack of a clear traceability mechanism can lead to uncertainty regarding regulatory compliance and ESG (Environmental, Social, and Governance) reporting. Companies that can demonstrate transparent sourcing are often better positioned to manage these reputational risks.
Investor Monitorables
Moving forward, the primary monitorable for investors is the operationalization of the Biological Diversity (Amendment) Act, 2023, and any subsequent regulatory changes that might adjust levy structures. As the NBA continues to refine its disbursement processes—evidenced by the recent Rs. 2.02 crore payout to 30 states and Union Territories—companies will need to align their internal compliance systems with these evolving requirements. Investors should watch for management commentary on compliance costs and how firms balance these mandatory contributions with their research and development spending.